[1]
Hemmer B., Archelos JJ., Hartung HP.: New concepts in the
immunopathogenis of multiple sclerosis Nat. Rev. Neurosci. 2002; 3:
291-301.
[2]
de Mol CL., Wong Y., van Pelt ED., et al.: The clinical spectrum and
incidence of anti-MOG-associated acquired demyelinating syndromes in
children and adults, Mult. Scler. 2019 May 16.
[3]
Thompson A.J, Banwell B., Barkhof F., et al.: Diagnosis of multiple
sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;
17: 162-173.
[4]
Krupp L.B, Tardieu M., Amato M.P., et al.: International Pediatric Multiple
Sclerosis Study Group criteria for pediatric multiple sclerosis and
immune-mediated central nervous system demyelinating disorders:
revisions to the 2007 definitions” Mult. Scler. 2013; 19: 1261-1267.
[5]
Tardieu M., Banwell B., Wolinsky J.S., et al.: „Consensus definitions for
pediatric MS and other demyelinating disorders in childhood“ Neurology
2016; 87: S8-S11.
[6]
Prőbstel AK, Dormair K., Bittner R. et al.: Antibodies to MOG are transient
in childhood ADEM Neurology 2011; 77: 580-588.
[7]
Hacohen Y., Absoud M., Deiva K. et al.: Myelin oligodendrocytes
glycoprotein antibodies predict a non-MS demyelination course in
children Neuroinflamm. 2015; 2: e81.
[8]
Ketelslegers IA., VanPelt DE., Bryde S. et al.: „Anti-MOG antibodies plead
against MS diagnosis in a acquired demyelinating syndromes cohort“
Mult. Scler. 2015: 12: 1513-1520.
[9]
Peschl P., Bradl M., Hoftberger R.,: Myelin oligodendrocyte glycoprotein:
deciphering a target in inflammatory demyelinating diseases Front
Immunol. 2017: 8: 529.
[10]
Hennes E.M., Baumann M., Schanda K., et al.: Prognostic relevance of
MOG antibodies in children with an acquired demyelinating syndrome
Neurology 2017; 89: 900-908.
[11]
Fernandez-Carbonell C., Vargas-Lowy D., Musallam A., et al.: “Clinical
and MRI phenotype of children with MOG antibodies” Mult. Sclr. 2016;
22: 174 – 184.
[12]
Hacohen Y., Wong YY. Lechner C. et al.: Disease course and treatment
responses in children with relapsing myelin oligodendrocyte glycoprotein
antibody – associated disease JAMA Neurol. 2018 Apr; 75: 478-487.
[13]
Wynford-Thomas R., Jacob A., Tomassini V.: Neurological update: MOG
antibody disease Journal of Neurology 2019; 266: 1280-1286.
Scholar Google
PubMed